We found that rediscovery (the percentage of known actives present in the de novo-generated compounds), was greater in public projects (1.60%, 0.64%, and 0.21% of the top 100, 500, and all 5,000 generated compounds, respectively) than that in in-house projects (where the values were 0.00%, 0.03%, and 0.04%, respectively). This shows that the public dataset which was mapped on a pseudo-time axis behaves fundamentally different from a real-world drug discovery project, leading to very different numerical results.